In summary, the critical role of the cancer cell‐intrinsic SMYD3‐SREBP1‐CD47 axis is elucidated in regulating the immune microenvironment in ccRCC and provides a potential therapeutic strategy to manipulate the tumor immune milieu in favor of antitumor immunity. Here, SMYD3 is linked to nonpapillary renal cell carcinoma.